Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C.; Schultz, N.; Walch, H.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Effectiveness of sentinel lymph node mapping in gastric cancer
    Meeting Abstract

    Abate, M. E.; Drebin, H. M.; Fei, T.; Poruk, K.; Neuwirth, M.; Ferguson, B.; Shimada, S.; Tang, L.; Vardhana, S.; Strong, V. E.
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Meeting Abstract

    Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
    Meeting Abstract

    Wainberg, Z.; Melisi, D.; Macarulla, T.; Cid, R. P.; Chandana, S.; de la Fouchardiere, C.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
    Meeting Abstract

    Randon, G.; Aoki, Y.; Cohen, R.; Nasca, V.; Klempner, S.; Maron, S.; Cerantola, R.; Fornaro, L.; Ambrosini, M.; Manca, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Chan, S.; Kelley, R.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y.; Galle, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
    Meeting Abstract

    Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Meeting Abstract

    Harding, J.; Ikeda, M.; Goyal, L.; Rodon, J.; Bai, L.; Oh, D.; Park, J.; Chen, L.; Ueno, M.; Liao, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Meeting Abstract

    Valle, J.; Abou-Alfa, G.; Kelley, R.; Lowery, M.; Shroff, R.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save